Article: New Torcetrapib/Atorvastatin Research Further Supports Raising 'Good' HDL Cholesterol.

* Torcetrapib/Atorvastatin Clinical Trial Program is the Largest Ever Conducted by Pfizer: 25,000 Patients Enrolled in Studies Underway Around the World * Pfizer Clinician: "First Data to Show that there are Important Differences in Raising HDL Cholesterol Levels with Torcetrapib and Atorvastatin Depending on Whether it is Dosed in the Morning or Evening" * TNT Trial Investigator: "The TNT Sub-Analysis Suggests that HDL Cholesterol May Also Provide Important Therapeutic Benefits that May Result in Further Reductions in Cardiovascular Risk"

ATLANTA, March 14 /PRNewswire-FirstCall/ -- Pfizer said today that new data, involving its medicine in development ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!